A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
Taro Kishi,1 Yuki Matsuda,1 Shinji Matsunaga,1 Tomohiko Mukai,1,2 Masatsugu Moriwaki,1,2 Hideaki Tabuse,3 Kiyoshi Fujita,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 2Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, 3Department...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-11-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-randomized-trial-of-aripiprazole-vs-blonanserin-for-the-treatment-of-peer-reviewed-fulltext-article-NDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850157045108441088 |
|---|---|
| author | Kishi T Matsuda Y Matsunaga S Mukai T Moriwaki M Tabuse H Fujita K Iwata N |
| author_facet | Kishi T Matsuda Y Matsunaga S Mukai T Moriwaki M Tabuse H Fujita K Iwata N |
| author_sort | Kishi T |
| collection | DOAJ |
| description | Taro Kishi,1 Yuki Matsuda,1 Shinji Matsunaga,1 Tomohiko Mukai,1,2 Masatsugu Moriwaki,1,2 Hideaki Tabuse,3 Kiyoshi Fujita,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 2Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, 3Department of Psychiatry, Holy Cross Hospital, Toki, Gifu, Japan Objective: There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194).Methods: The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS) total score at week 24. Secondary outcomes were PANSS subscale scores, 21-item Hamilton Rating Scale for Depression (HAMD-21) score, response rate, discontinuation rate, and individual adverse events.Results: Forty-four patients were recruited. The discontinuation rate was 86.4% in the aripiprazole group and 68.2% in the blonanserin treatment group. There was no significant difference in mean time to discontinuation between the groups. Although both treatment groups showed significant reductions in the PANSS total score, PANSS subscale scores, and HAMD-21 scores at week 24, the magnitudes of the changes did not differ between the groups. There were no significant differences in the incidences of adverse events including somnolence, extrapyramidal symptoms, prolactin-related adverse events, and weight change between the groups.Conclusion: Our results suggest similar efficacy and safety profiles of aripiprazole and blonanserin in the patients with schizophrenia. Double-blind controlled studies are needed to further explore the efficacy and safety of aripiprazole and blonanserin in schizophrenia. Keywords: aripiprazole, blonanserin, schizophrenia, efficacy, safety, randomized trial |
| format | Article |
| id | doaj-art-65335503573241dbb9d066c252bf6fb2 |
| institution | OA Journals |
| issn | 1178-2021 |
| language | English |
| publishDate | 2016-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Neuropsychiatric Disease and Treatment |
| spelling | doaj-art-65335503573241dbb9d066c252bf6fb22025-08-20T02:24:17ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212016-11-01Volume 12Issue 13041304930252A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disordersKishi T0Matsuda YMatsunaga SMukai TMoriwaki MTabuse HFujita KIwata N1Department of PsychiatryDepartment of PsychiatryTaro Kishi,1 Yuki Matsuda,1 Shinji Matsunaga,1 Tomohiko Mukai,1,2 Masatsugu Moriwaki,1,2 Hideaki Tabuse,3 Kiyoshi Fujita,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 2Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, 3Department of Psychiatry, Holy Cross Hospital, Toki, Gifu, Japan Objective: There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194).Methods: The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS) total score at week 24. Secondary outcomes were PANSS subscale scores, 21-item Hamilton Rating Scale for Depression (HAMD-21) score, response rate, discontinuation rate, and individual adverse events.Results: Forty-four patients were recruited. The discontinuation rate was 86.4% in the aripiprazole group and 68.2% in the blonanserin treatment group. There was no significant difference in mean time to discontinuation between the groups. Although both treatment groups showed significant reductions in the PANSS total score, PANSS subscale scores, and HAMD-21 scores at week 24, the magnitudes of the changes did not differ between the groups. There were no significant differences in the incidences of adverse events including somnolence, extrapyramidal symptoms, prolactin-related adverse events, and weight change between the groups.Conclusion: Our results suggest similar efficacy and safety profiles of aripiprazole and blonanserin in the patients with schizophrenia. Double-blind controlled studies are needed to further explore the efficacy and safety of aripiprazole and blonanserin in schizophrenia. Keywords: aripiprazole, blonanserin, schizophrenia, efficacy, safety, randomized trialhttps://www.dovepress.com/a-randomized-trial-of-aripiprazole-vs-blonanserin-for-the-treatment-of-peer-reviewed-fulltext-article-NDTAripiprazoleBlonanserinSchizophreniaEfficacySafetyRandomized trial |
| spellingShingle | Kishi T Matsuda Y Matsunaga S Mukai T Moriwaki M Tabuse H Fujita K Iwata N A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders Neuropsychiatric Disease and Treatment Aripiprazole Blonanserin Schizophrenia Efficacy Safety Randomized trial |
| title | A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders |
| title_full | A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders |
| title_fullStr | A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders |
| title_full_unstemmed | A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders |
| title_short | A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders |
| title_sort | randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders |
| topic | Aripiprazole Blonanserin Schizophrenia Efficacy Safety Randomized trial |
| url | https://www.dovepress.com/a-randomized-trial-of-aripiprazole-vs-blonanserin-for-the-treatment-of-peer-reviewed-fulltext-article-NDT |
| work_keys_str_mv | AT kishit arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT matsuday arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT matsunagas arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT mukait arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT moriwakim arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT tabuseh arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT fujitak arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT iwatan arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT kishit randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT matsuday randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT matsunagas randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT mukait randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT moriwakim randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT tabuseh randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT fujitak randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT iwatan randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders |